Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
Hydrochlorothiazide was granted FDA approval on 12 February 1959.
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 384
- Registration Number
- NCT00698646
- Locations
- 🇺🇸
Investigative Site, Taylors, South Carolina, United States
🇺🇸Investigative Sites, Pismo Beach, California, United States
🇺🇸Investigative site, St George, Utah, United States
The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose
- Conditions
- Hypertension
- Interventions
- Drug: Placebo with concomitant losartan or lisinopril
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 537
- Registration Number
- NCT00673790
- Locations
- 🇺🇸
Forest Investigative Site 117, Riverside, California, United States
🇺🇸Forest Investigative Site 072, Atlanta, Georgia, United States
🇺🇸Forest Investigative Site 006, Oxon Hill, Maryland, United States
A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00671424
- Locations
- 🇺🇸
GSK Investigational Site, Columbus, Ohio, United States
Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Kyushu University
- Target Recruit Count
- 207
- Registration Number
- NCT00670787
- Locations
- 🇯🇵
Department of Medicine and Clinical Science, Kyushu University, Fukuoka City, Fukuoka, Japan
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 564
- Registration Number
- NCT00667719
- Locations
- 🇹🇷
Investigative Site, Turkey, Turkey
Black Education and Treatment of Hypertension (BEAT HTN)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 99
- Registration Number
- NCT00661895
- Locations
- 🇺🇸
Creighton Community Health Center, Omaha, Nebraska, United States
18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
- Conditions
- Type 2 DiabetesHypertension
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2010-07-13
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 207
- Registration Number
- NCT00654745
Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2500
- Registration Number
- NCT00649389
Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00649324
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Factorial Study of Metoprolol Succinate TOPROL-XL (324A)
- Conditions
- High Blood Pressure (Hypertension).
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1900
- Registration Number
- NCT00642096
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.